Boyman O1, Kaegi C1, Akdis M2,3, Bavbek S4, Bossios A5, Chatzipetrou A6, Eiwegger T7, Firinu D8, Harr T9, Knol E10, Matucci A11, Palomares O12, Schmidt-Weber C13, Simon HU14, Steiner UC15, Vultaggio A11, Akdis CA2,3, Spertini F16
Abstract: Biologic agents (also termed biologicals or biologics) are therapeutics that are synthesized by living organisms and directed against a specific determinant, for example, a cytokine or receptor. In inflammatory and autoimmune diseases, biologicals have revolutionized the treatment of several immune-mediated disorders.
Biologicals have also been tested in allergic disorders. These include agents targeting IgE; T helper 2 (Th2)-type and Th2-promoting cytokines, including interleukin-4 (IL-4), IL-5, IL-9, IL-13, IL-31, and thymic stromal lymphopoietin (TSLP); pro-inflammatory cytokines, such as IL-1β, IL-12, IL-17A, IL-17F, IL-23, and tumor necrosis factor (TNF); chemokine receptor CCR4; and lymphocyte surface and adhesion molecules, including CD2, CD11a, CD20, CD25, CD52, and OX40 ligand. In this task force paper of the Interest Group on Biologicals of the European Academy of Allergy and Clinical Immunology, we review biologicals that are currently available or tested for the use in various allergic and urticarial pathologies, by providing an overview on their state of development, area of use, adverse events, and future research directions.
KEYWORDS:allergic rhinitis; asthma; atopic dermatitis; eosinophilic disorders; food allergy; hymenoptera allergy; urticaria
PMID: 25819018 [PubMed - in process]
PMID: 25819018 [PubMed - in process]
No comments:
Post a Comment